Alza
This article was originally published in The Tan Sheet
Executive Summary
Receives "approvable" letter from FDA on June 30 for chlorpheniramine maleate extended-release 8 mg and 16 mg tablets. The NDA was filed by Alza in September 1987. The 24-hour OTC antihistamine product is based on Alza's OROS controlled-release technology that is also the basis for 24- hour nasal decongestant Efidac/24, marketed by Ciba under a royalty-bearing licensing agreement ("The Tan Sheet" June 28, p. 5). Ciba also will market the controlled-release chlorpheniramine.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning